Using survival age as a screen, converting it into a terminal-value argument, and the three tests that separate a business which has merely lasted from one that has compounded.
1. Use age as a first-pass survival screen, and justify it with the base rate
The repeatable method
- Start from the failure base rate, not from the survivors: roughly half of all businesses are gone in five years and four-fifths in ten.
- Filter a universe by continuous corporate age — 100 years is the threshold used here — and treat what remains as having passed a test no financial statement can replicate.
- Read the age as evidence of adaptability, not of stability: ask what the business abandoned in order to survive.
- Apply Lindy only to things that do not age biologically — institutions, standards, brands, networks. It says nothing about a person, a patent, or a product.
- Treat the output as a candidate universe, then run your normal quality and valuation work on it.
Here: "50% of all businesses fail within 5 years; 80% of all businesses are gone within 10 years," against companies founded in 1837 (DE), 1879 (CVX), 1883 (PPG) and 1886 (JNJ). MMM is the cleanest illustration of adaptability: founded to mine corundum, it "quickly pivoted" and survived by abandoning its original purpose entirely.
Watch for
- Survivorship bias in the supporting evidence: a portfolio of companies selected today for being 100 years old could not have been assembled in 2000, which is when the cited backtest starts.
- Legal continuity mistaken for business continuity — a name that survived through bankruptcy, bailout or merger is not the same entity that started.
2. Convert expected corporate lifespan into an explicit terminal-value argument
The repeatable method
- State the claim in discounting terms: value equals all future cash flows discounted to today, so a longer expected life mechanically adds value.
- Estimate, however roughly, how many more years of cash flow you are underwriting — and notice how much of a typical valuation sits beyond year ten.
- Where the business is genuinely Lindy, allow yourself a longer explicit forecast horizon; where it is not, cut the horizon rather than the growth rate.
- Sanity-check the other direction: what would have to be true for the business to be gone in fifteen years? If the answer is nothing you can name, the age argument is doing real work.
Here: "The value of a business depends on all the cash it will generate in the future (discounted to today)… For investors, a longer life means more future cash flow." That single sentence converts a piece of folk wisdom into a valuation input, and it is what makes the issue more than a history lesson.
Watch for
- Terminal value doing all the work — an argument that can only be settled decades from now cannot be falsified now.
- Discount rates: at any realistic rate, cash flows beyond thirty years contribute very little, so the Lindy premium is smaller than it feels.
3. Separate "survived" from "compounded" before treating the screen as a buy list
The repeatable method
- For every name the age screen produces, pull the ten-year return alongside the multi-decade one.
- Where the two disagree sharply, the business has been durable but the shares have not — usually a sign the price already embedded the durability.
- Require a second, independent reason to own it: a price, a re-rating, an operational turn. Age alone is a reason to study, never a reason to buy.
- Do the same for the list as a whole: count how many of the names produced their return before your holding period would have started.
Here: the issue supplies its own counter-examples and does not hide them. DIS: "relatively flat over the past decade. But since 1990, it's up more than 1,300%." BAC: also about 1,300% since 1990, against JNJ's 8,000% and MCO's 6,000% since 2000 alone. And no valuation, fair value or expected return appears anywhere in the issue.
Watch for
- A list published without prices being read as a list of buys — the same names carry hard fair values in this archive's portfolio updates and none is given here.
- Total-return figures measured from 1990, which flatters anything that was cheap in 1990 regardless of the business.
4. Classify durability into three testable kinds rather than accepting "great brand"
The repeatable method
- Ask first whether the underlying need is permanent — food, shelter, health, energy, payment, safekeeping, story. If the need can disappear, nothing else matters.
- Then ask whether the company owns something physically or institutionally irreplaceable — a network, an installed base, a licence, a trust position.
- Then ask whether the economic model has migrated away from the capital-hungry part of the industry towards fees, rent or royalties.
- Score each name on all three. One alone is weak; the durable compounders on this list score on at least two.
Here: permanent need — "Food is a fundamental human need"; "People will always need healthcare"; "People will always need a safe place to keep their money." Irreplaceable network — Chevron's infrastructure "almost impossible to recreate today," PepsiCo's distribution "almost impossible to match," Moody's trust position. Model migration — MCD "is essentially a real estate company that collects rent and royalties" and MAR "earns fees without owning most of its hotels."
Watch for
- A permanent need served by a replaceable supplier — the need for energy does not guarantee any particular energy company.
- Fee-based models whose fee is set by the party paying it: franchisees and hotel owners renegotiate.
5. Read the omissions in a durability list as carefully as the arguments
The repeatable method
- For each name on any published list, write down the one obvious current controversy — the litigation, the demand shock, the disrupted segment.
- Check whether the author addressed it. Silence on a live issue is information about the format, not about the risk.
- Distinguish long-horizon framing (which legitimately ignores this quarter) from selective omission (which ignores a threat to the terminal value itself).
- Only the second is disqualifying — but you have to name it yourself, because the list will not.
Here: MMM is presented on innovation and embeddedness with no mention of the multi-billion-dollar settlements of recent years; PEP on distribution with no mention of the weight-loss-drug demand question tracked elsewhere in this research hub; BAC on switching costs and regulation with no mention of 2008. Each of those is a terminal-value question, not a quarterly one.
Watch for
- Format-driven optimism: a "timeless businesses" piece has no natural place to put a risk, which is precisely why the reader must supply one.
- Your own reluctance to spoil an appealing story — the omissions are always the comfortable ones.
Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.